Special thanks to our clinical collaborators Special thanks to our patients. Administration. Andre Baretto
|
|
- Alvin Phelps
- 6 years ago
- Views:
Transcription
1 Antibody-mediated rejection: a prototype for antibody-mediated diseases Phil Halloran Alberta Transplant Applied Genomics Centre Edmonton, Canada Disclosures PFH has shares in TSI a university spinoff company with an interest in molecular diagnostics Acknowledgements: The current Edmonton ATAGC team Andre Baretto Jessica Chang Collaborators: Konrad Famulski Arthur Matas Luis Hidalgo Michael Picton Anna Hutton Jon Bromberg Vido Ramassar Daniel Seron Jeff Reeve Jeffery Venner Declan de Freitas Gunilla Einecke Alexandre Loupy Joana Sellares Administration Michelle Ryan Novartis Pharmaceuticals Corporation Stromedix, Inc. Bristol-Myers Squibb Astellas Pharma Inc. Roche Molecular Systems, Roche Canada Alberta Health Services University Hospital Foundation Roche Organ Transplantation Research Foundation Genome Canada Alberta Advanced Education and Technology Canada Foundation for Innovation Alberta Heritage Foundation for Medical Research Muttart Chair in Clinical Immunology Special thanks to our clinical collaborators Special thanks to our patients
2 Antibody-mediated kidney rejection The leading cause of organ transplant loss Type 1 (early-presensitized) Type 2 (late-de novo, usually after one year) Active or inactive (microcirculation inflammation) At least 50% is currently missed (C4d ve) Molecular correlates: Rejection transcripts : largely IFNG effects Donor-specific antibody (DSA) associated transcripts NK cell transcripts Endothelium transcripts Transcripts associated with progression and scarring Learning points about ABMR based on lessons from kidney transplant biopsies The target is the microcirculation endothelium May be active or inactive: large dynamic range If severe, it compromises blood flow: ischemia Usually operates as a stress on the microcirculation that can be accommodated for variable periods on time Time-dependent lesions: transplant glomerulopathy Often currently missed: C4d is unreliable No truly specific histologic features Probably need molecular pathology readouts There is something special about class II No clear evidence that autoantibody can mediate ABMR Requires biopsy diagnosis: DSA alone is not specific Unmet need Evidence-based medicine Precision diagnosis
3 The unmet need: pathologists admit that histology is not good enough In 2003 Furness et al wrote that agreement between pathologists using the same lesions and rules was not only poor, but resistant to improvement by training.... international variation in histologic grading is large, under-recognized, recognized, difficult to improve, and almost certainly of major clinical relevance. Urgent steps are required to improve this area of clinical practice. * Thus improvement will NOT come from histology alone. *Furness PN, Taub N, Assmann KJ, Banfi G, Cosyns JP, Dorman AM, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibilit Am J Surg Pathol 2003;27(6): Reproducibility of assessment of histological features P N Furness and N Taub for the Convergence of European Renal Transplant Pathology Assessment Procedures (CERTPAP) Project KI 60:1998, 2001 Feature Kappa Tubulitis Banff grade 0.17 Tubulitis per 10 HPF 0.16 Tubular atrophy 0.29 Glomeruli: number present 0.53 Early type of allograft glomerulitis 0.21 Number of glomeruli completely sclerosed 0.47 Mesangial matrix increase 0.12 Glomeruli with segmental sclerosis 0.13 Chronic allograft glomerulopathy 0.11 Mononuclear cell interstitial infiltration 0.34 Interstitial fibrosis 0.30 Number of arterial cross sections 0.19 Arteriolar hyaline thickening 0.11 Endothelial cell activation arterial 0.21 Endothelial cell activation venous 0.10 Neutrophils in peritubular capillaries 0.13 Intimal arteritis 0.35 Arteriolitis 0.24 Fibrous intimal thickening 0.36 Breaks in arterial elastica 0.22 Inflammatory cells in intima in chronic fibrosis 0.34 Kappa values: A measure of how much 2 observers agree compared to chance: Perfect = 1 Chance = 0 Evidence-based medicine requires real evidence US Preventive Services Task Force (USPSTF) Systems to stratify evidence by quality have been developed, such as this one by the USPSTF for ranking evidence about the effectiveness of treatments or screening (or diagnosis?): Level I: at least one properly designed randomized controlled trial. Level II-1: well-designed controlled trials without randomization. Level II-2: well-designed cohort or case-control analytic studies, preferably from more than one center or research group. Level II-3: multiple time series with or without the intervention. Dramatic results in uncontrolled trials Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. Histology is here: Opinion and consensus is not good enough to guide precision medicine for serious illnesses
4 Why histology diagnoses are not a gold standard Lack of objective prospective studies! Uses non-specific lesions with low kappa values Requirement for subjective interpretation of rules e.g. too atrophic Incorrect rules e.g. ABMR Requirement for C4d staining: 2/3 are negative Isolated v-lesion=tcmr: 80% wrong often ABMR Inherent ambiguity Borderline Changing times since 1991: altered probabilities Less rejection, much more injury Lessons from 2 prospective consented studies of indication biopsies Genome Canada: 2005 present: 403 biopsies, 315 patients INTERCOM: 2011-present: 300 biopsies in 264 patients plus Paris collaboration (Alexandre Loupy): presensitized Hannover: 105 protocol biopsies Edmonton heart transplants: 106 biopsies Contents History of ABMR: clinical phenotype Molecular phenotype and diagnosis Prognosis and natural history Relationship to non-adherence
5 Peter B Medawar and Peter Gorer Peter Medawar Peter Gorer: died 1961 Historical accident Did the death of Peter Gorer cause transplant to underestimate the role of alloantibody for 40 years? But Paul Terasaki kept the flame alive Transplantation 49:85-91,1990 Description of antibody mediated rejection: a microcirculation disease with DSA distinct from T cell-mediated rejection
6 Alloantibody Mediated Rejection: alloantibody-mediated attack by cells on the microcirculation PTC Inflammatory Cells The disease is microcirculation inflammation (g, ptc) but lesions are non-specific C4d has been useful but many false ve, some false +ve Clin Exp Immunol 86: ,1991 Association of capillary C4d staining with severe rejection, suggesting a role for antibody in post transplant rejection syndromes C4 splits into C4d b A marker, not a mechanism? a1 a3 a2(=c4d) a4 Thioester bond covalently binds tissue H. E. Feucht. Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity. Am.J.Transplant. 3 (6): , 2003 g
7 J Am Soc Nephrol 12: , Association of capillary C4d staining with TG and chronic rejection TG is a time dependent feature: Rare before 1 year But lesions are not specific Double contours in transplant glomerulopathy TG JASN 13: , 2002: The full C4d+ve phenotype: Peritubular capillaritis, transplant glomerulopathy
8 AJT 9: ,2009: Many kidneys with late C4d negative ABMR fail but are being misdiagnosed: the disease is really microcirculation inflammation with DSA C4d+ve ABMR C4d-ve ABMR (nonadherence!) Recurrent GN AKI, TCMR, CNI, etc Outcomes in 315 biopsied patients: Time of biopsy affects risk: time-dependent diseases 403datalock = 315 Patients p= 1.11e-06 Einecke G, et al. Am J Transplant. 2009;9(11): The molecular microscope A central diagnostic system that uses microarray measurement of transcripts in a renal biopsy core to interpret the state of a kidney transplant Molecular Uses predefined measurements to estimate: Microscope Probability of TCMR Probability of ABMR Extent of acute kidney injury (AKI) Extent of atrophy-scarring Prognosis (Interesting point: no signal from CNI toxicity )
9 AJT 9: , 2009: The transcripts associated with all rejection (ABMR, TCMR, mixed) are mostly IFNG-induced transcripts (CXCL9/10/11, GBPs, MHC, INDO, etc) AJT 9: , 2009 Separation of rejection from non-rejection but revealed interesting apparent histology false positives e.g. pretreatment Reeve et al AJT 9: , 1810, 2009 Many of the genes selected by association with rejection were IFNG-induced, suggesting that IFNG is produced by both in TCMR (effector T cells) and ABMR (by NK cells triggered through Fc receptors?)
10 AJT 9: , 2009: Endothelial l transcripts t are increased in late C4d +ve but are also increased in many late cases that are C4d negative: C4d -ve ABMR Sis al AJT 9: , 2323, 2009 Endothelial transcripts identified from the literature were abnormal in many diseases but provided some separation of ABMR from TCMR: proof of concept Normal kidney TCMR ABMR AJT 10: ,2010: DSA-associated transcripts: Association of ABMR with NK markers and IFNG effects as well as microcirculation transcripts
11 Hidalgo et el AJT 10: , ,2010 In late indication biopsies the DSASTs included endothelium NK, and IFNG-induced transcripts Problem: some sharing with effector T cells AJT 13: ,2013 TCMR score correlates with tubulitis and interstitial infiltrate, and with unanimity among pathologists A minority of borderline, and some cases of PVN actually have TCMR TCMR score indicates many errors in inflamed biopsies: false positives due to early or late tissue injury and isolated v lesions No effect on graft survival When one pathologist diagnoses TCMR, another agrees only 45% of the time Reeve et al AJT 13: ,2013
12 Reeve et al AJT 13: ,2013 TCMR score V-lesions alone are not reliable for diagnosing TCMR: Only 5/24 were actually molecular TCMR AJT 13: ,2013 TCMR diagnosed by the TCMR score (microarray) does not affect future graft survival Death censored survi ival probability BFC403 dataset: 315 patients TCMR Other Dx Edmonton Genome Canada study and INTERCOM: unpublished 2012 TCMRprob<0.1 N=279 F=71 TCMRprob>0.1 N=36 F=10 TCMRprob >0.1 TCMRprob < Event time (days)
13 April 2013 AJT Algorithm for the ABMR classifier Sellares et al April 2013 AJT Sellares et al April 2013 AJT
14 The ABMR score correlates with microcirculation lesions in the 403 indication biopsies ABMR score > ABMR score Gamma 0.2 [n=90] <0.2 [n=313] statistic B Median time of biopsy post transplant (months) *** Mean histologic lesion scores Peritubular capillaritis: ptc-score *** ABMR related lesions TCMR related lesions TCMR/ ABMR related lesion Glomerulitis: g-score *** Transplant glomerulopathy: cgscore *** Interstitial inflammation i-score * Tubulitis t-score Intimal arteritis v-score Interstitial fibrosis: ci-score *** Atrophy-scarring related lesions Tubular atrophy: ct-score *** Arterial fibrous intimal ** thickening: cv-score Arteriolar hyalinosis: ah-score *** April 2013 AJT The ABMR score correlates with DSA positivity at the time of biopsy ABMR score DSA positive (Class II or I/II) HLA antibody not demonstrably donor-specific (NDSA) HLA antibody negative Not done B TOTAL > (35) (20) < (40) TOTAL 124 (95) April 2013 AJT The positive ABMR score more powerfully predicts subsequent graft loss than any histologic definition of ABMR Univariable results LL Hazard Ratio UL p-value Molecular ABMR score B x10-12 Histology-DSA ABMR (C4d+/-/mixed) x10-8 Histology-DSA C4d+ ABMR(both alone and mixed) Histology-DSA C4d- ABMR (both alone and mixed) x10-6 Multivariable results C Molecular ABMR score B x10-4 Histology-DSA ABMR (C4d+/-/mixed) April 2013 AJT
15 ABMR diagnosed by the ABMR Score (microarray) severely reduces future graft survival Death censored surv vival probability ABMRprob<0.2 N=247 F=44 ABMRprob>0.2 N=68 F=37 Other diagnoses ABMR ABMRprob<0.2 ABMRprob>0.2 BFC403 dataset: 315 patients Event time (days) Attribution of failures in the Genome Canada study
16 TCMR score Histologic TCMR Borderline Failures ABMR score Histologic ABMR Non adherence Mixed unpublished Figure 1b. Distribution of attributed causes of failure in failed grafts [n=60] p1 PVN 7% Medical conditions 10% Missing Data 5% 65% ABMR, probable ABMR, or mixed GN 13% ABMR 47% Nonadherent 48% Adherent 52% Mixed 5% Probable ABMR 13% Some late ABMR/mixed is due to non-adherence BUT what about the rest? Sellares et al AJT 12: 388, 2012 Progress is slow 1990: Recognition of ABMR as a microcirculation process distinct from TCMR, an interstitial-epithelial epithelial process 1991: Description of C4d staining 1998: ABMR meeting in Montreal 2001: Uptake by Banff required C4d: error 2009: Recognition of C4d negative ABMR 2011: continuing failure of histology consensus 2013: description of molecular ABMR score
17 Slide 47 p1 no titles usually on figures, just legends phil, 3/24/2011
18 Patent 1897 Technology adoption is very slow: the story of Rudolph Diesel Invented the high-compression Diesel internal combustion engine: patented 1897 Thermal efficiency of 50% vs 6% for steam engines Widespread adoption took 60 years Institutional inertia Vested interest resistance Technical challenges Costs of new technology Rudolf Diesel met a mysterious end in September of 1913: boarded SS Dresden on a trip to England his body was found days later floating in the sea Suicide? Financial problems Murder? Strategic and corporate issues Dieselization of railroads: >1950 The problem is compacency Histology is good enough I like my horse Who needs a car? What we have discussed History of ABMR: clinical phenotype Molecular phenotype and diagnosis Prognosis and natural history Relationship to non-adherence
19 Thank you
The transcriptome of the renal transplant biopsy: the lessons. Philip F Halloran
The transcriptome of the renal transplant biopsy: the lessons Philip F Halloran Alberta Transplant Applied Genomics Centre April 27 th 2009 Congratulations on your 50 th anniversary ATAGC Learning objectives:
More informationATAGC TSI ATAGC TSI ATAGC TSI
November 6th @ 8-8:30am Molecular diagnosis of rejection in renal transplant biopsies: new insights into outcomes Phil Halloran Alberta Transplant Applied Genomics Center and Transcriptome Sciences Inc
More informationNovember 8-8:30am Molecular diagnosis of rejection in renal transplant biopsies: new insights into outcomes
November 6th @ 8-8:30am Molecular diagnosis of rejection in renal transplant biopsies: new insights into outcomes Phil Halloran Alberta Transplant Applied Genomics Center and Transcriptome Sciences Inc
More informationStatement of Disclosure
Statement of Disclosure Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma Treatment of Acute ABMR AstraZeneca Treatment
More informationThe Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference
The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Statement of Disclosure Mark
More informationImproving Organ Transplant Management. Improving Organ Transplant Management
Improving Organ Transplant Management MODERATOR John Gill, MD Providence Health Care, Vancouver, Canada SPEAKERS Understanding Events in Organ Transplant: Lessons from the Molecular Microscope Philip F.
More informationRenal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic
Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney
More informationBiopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Biopsy Features of Kidney Allograft Rejection Banff 2017 B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Treatment of allograft dysfunction should rely on the biopsy findings
More informationKidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA
Kidney Summary Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Key Issues to Address re: the Classification 1. Incorporation of i-ifta + tubulitis into the TCMR classification - Defining
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationThe Force is in the Tissue
The Force is in the Tissue The tissue changes have the last word! Michael Mengel and Phil Halloran Alberta Transplant Applied Genomics Centre () http://atagc.med.ualberta.ca/services/molecularmicroscopesystem
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More informationPathology of Kidney Allograft Dysfunction. B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Pathology of Kidney Allograft Dysfunction B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary The gold standard for exploration of the cause of an allograft dysfunction is to perform
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationChronic Active TCMR: clinical implications
Chronic Active TCMR: i, iatr, i-ifta, and the clinical implications Roslyn B. Mannon, M.D. Professor of Medicine, Division of Nephrology Professor of Surgery, Division of Transplantation Director of Research,
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationPathological back-ground of renal transplant pathology and important mile-stones of the Banff classification
Banff 1 Banff Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital Morozumi Kunio,
More informationThe Histology of Kidney Transplant Failure: A Long-Term Follow-Up Study
CLINICAL AND TRANSLATIONAL RESEARCH The Histology of Kidney Transplant Failure: A Long-Term Follow-Up Study Maarten Naesens, 1,2,6 Dirk R.J. Kuypers, 1,2 Katrien De Vusser, 1,2 Pieter Evenepoel, 1,2 Kathleen
More informationSCORING OF i-ifta: POTENTIAL RULES & ROLE IN CHRONIC TCMR
SCORING OF i-ifta: POTENTIAL RULES & ROLE IN CHRONIC TCMR Parmjeet Randhawa, MD Professor of Pathology The Thomas E Starzl Transplantation Institute University of Pittsburgh . I HAVE NO CONFLICTS OR FINANCIAL
More informationUpdate on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University of Tennessee Health Science Center
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationPathology of Kidney Allograft Dysfunction. B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary
Pathology of Kidney Allograft Dysfunction B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary The renal biopsy is a powerful tool in the diagnostic evaluation of allograft dysfunction
More informationHLA Part II: My Patient Has DSA, Now What?
2017 CST-Astellas Canadian Transplant Fellows Symposium HLA Part II: My Patient Has DSA, Now What? James Lan, MD, FRCPC, D(ABHI) Dr. Lan completed his nephrology training at the University of British Columbia.
More informationThe Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology The Harvard community has made this article openly available. Please
More informationEvolution of the approaches toward grading and classifying chronic changes in the renal allograft: Banff classification updates III
EDITORIAL Advance Access publication 24 February 2014 Evolution of the approaches toward grading and classifying chronic changes in the renal allograft: Banff classification updates III Histopathology
More informationThe Banff Conferences on renal allograft pathology the latest 2013 report
615245PSH0010.1177/2010105815615245Proceedings of Singapore HealthcareLoh research-article2015 Review Article PROCEEDINGS OF SINGAPORE HEALTHCARE The Banff Conferences on renal allograft pathology the
More informationDSA Positive and then To biopsy or not?
DSA Positive and then To biopsy or not? Banff SCT 2017 29 March 2017 Peter Nickerson, MD, FRCPC, FCAHS Flynn Family Chair in Renal Transplantation Professor of Internal Medicine and Immunology Relevant
More informationHistopathological evaluation of renal allograft biopsies in Nepal: interpretation and significance
Nepal Medical Association Building Exhibition Road, Kathmandu Journal of Pathology of Nepal (2012) Vol. 2, 172-179 Association of Clinical Pathologist of Nepal-2010 Journal of PATHOLOGY of Nepal www.acpnepal.com
More informationHistopathological findings in transplanted kidneys
Katsuma et al. Renal Replacement Therapy (2017) 3:6 DOI 10.1186/s41100-016-0089-0 REVIEW Histopathological findings in transplanted kidneys Ai Katsuma, Takafumi Yamakawa, Yasuyuki Nakada, Izumi Yamamoto
More informationLe Rejet Humoral Chronique en 2010: Histoire naturelle et problématiques
Le Rejet Humoral Chronique en 2010: Histoire naturelle et problématiques CAMR in 2010: natural history and perspectives Alexandre Loupy 1 Introduction 2 CAMR: the missing link 3 Natural history of CAMR
More informationRisk Factors in Long Term Immunosuppressive Use and Advagraf. Daniel Serón Nephrology department Hospital Universitari Vall d Hebron
Risk Factors in Long Term Immunosuppressive Use and Advagraf Daniel Serón Nephrology department Hospital Universitari Vall d Hebron Progressive well defined diseases ABMR GN Polyoma Non-specific Findings
More informationUpdate on Transplant Glomerulopathy
Update on Transplant Glomerulopathy Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Methodist University Hospital, Transplant Institute Division of Transplantation, Department
More informationMOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic. Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy
MOLECULAR PREDICTORS OF OUTCOME Ondrej Viklicky, Prague, Czech Republic Chair: Daniel Abramowicz, Brussels, Belgium Rosanna Coppo, Turin, Italy Prof Ondrej Viklicky Department of Nephrology Transplant
More informationTransplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury
Transplant Webinar Series: Ep. 9 Biomarkers for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 2015 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationInterpreting Macrophage Transcripts In Human T Cell-Mediated Rejection
Interpreting Macrophage Transcripts In Human T Cell-Mediated Rejection by Dina El Sayed Feisal Amin Badr A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy
More informationFuture Webinars. Handouts 18/09/ Program-Handouts.aspx
Transplant Webinar Series: Ep. 9 Bio for Post-Transplant Immune Injury Future Webinars Link to register: https://immucor.webinato.com/register All Content 215 Immucor, Inc. Handouts http://www.immucor.com/en-us/pages/educational-
More informationBanff 09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups
American Journal of Transplantation 2010; 10: 464 471 Wiley Periodicals Inc. Meeting Report C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society
More informationSince the first Banff meeting in 1991, the diagnosis and
CLINICAL AND TRANSLATIONAL RESEARCH Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d Michelle Willicombe, 1,5 Candice Roufosse, 2 Paul Brookes, 3 Adam G. McLean 1, Jack Galliford,
More informationHistopathology: Hypertension and diabetes in the kidney These presentations are to help you identify basic histopathological features.
Histopathology: Hypertension and diabetes in the kidney These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need
More informationInterpretation of Renal Transplant Biopsy. Arthur H. Cohen Wake Forest University School of Medicine Winston-Salem, North Carolina USA
Interpretation of Renal Transplant Biopsy Arthur H. Cohen Wake Forest University School of Medicine Winston-Salem, North Carolina USA Renal Transplant Biopsies Tissue Processing Ideal world process as
More informationDiagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape
Diagnosis and Management of Acute and Chronic Humoral Rejection Lars Pape Immunosuppression Acute rejection Chronic rejection Side effects Infections Nephrotoxicity Adult population Nearly all late rejection-related
More informationProf. Sandrine Florquin Department of Pathology Academic Medical Center University of Amsterdam Amsterdam, The Netherlands. Slide 1.
Interleukin 17 in renal biopsies as risk factor for progression Sandrine Florquin, Amsterdam, The Netherlands Chairs: Mohamed R. Daha, Leiden, The Netherlands Pierre Ronco, Paris, France Prof. Sandrine
More informationOrdering Physician. Collected REVISED REPORT. Performed. IgG IF, Renal MCR. Lambda IF, Renal MCR. C1q IF, Renal. MCR Albumin IF, Renal MCR
RenalPath Level IV Wet Ts IgA I Renal IgM I Renal Kappa I Renal Renal Bx Electron Microscopy IgG I Renal Lambda I Renal C1q I Renal C3 I Renal Albumin I Renal ibrinogen I Renal Mayo Clinic Dept. of Lab
More informationJames E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant
James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest
More informationInterstitial Inflammation
Interstitial Inflammation Currently considered to be T cell-mediated process Plasma cell rich acute rejection often associated with AMR Preliminary data suggests that interstitial follicular helper T cells
More informationClassification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus
Classification of Glomerular Diseases and Defining Individual Glomerular Lesions: Developing International Consensus Mark Haas MD, PhD Department of Pathology & Laboratory Medicine Cedars-Sinai Medical
More informationPersonal Viewpoint. The Beginning. Banff Process, Lesions and Classification. M. Mengel a,,b.sis a,b and P. F. Halloran a
American Journal of Transplantation 2007; 7: 2221 2226 Blackwell Munksgaard Personal Viewpoint C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society
More informationPathology. Consortium of renal pathologist. Pathologists
Consortium of 15-17 renal pathologist Pathology Had several sessions to discuss Following Cambridge modification of Remuzzi Discussed each variable to define how to do as uniformly as possible 30 Cambridge
More informationSurgical Pathology Report
Louisiana State University Health Sciences Center Department of Pathology Shreveport, Louisiana Accession #: Collected: Received: Reported: 6/1/2012 09:18 6/2/2012 09:02 6/2/2012 Patient Name: Med. Rec.
More informationDr Ian Roberts Oxford
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Present the basic diagnostic features of the commonest conditions causing renal failure Highlight diagnostic pitfalls. Crescentic GN: renal
More informationImmunopathology of T cell mediated rejection
Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant
More informationMicroarray Analysis of Rejection in Human Kidney Transplants Using Pathogenesis-Based Transcript Sets
American Journal of Transplantation 2007; 7: 2712 2722 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationRecognition and Treatment of Chronic Allograft Dysfunction
Recognition and Treatment of Chronic Allograft Dysfunction Alexander Wiseman, M.D. Associate Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas Transplant Programs
More informationResearch Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting Antibody-Mediated Rejection
Clinical and Developmental Immunology Volume 2013, Article ID 460316, 6 pages http://dx.doi.org/10.1155/2013/460316 Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting
More informationIntroduction. TCMR, T-cell-mediated rejection. Received 25 November 2008, revised 26 April 2009 and accepted for publication 02 May 2009
American Journal of Transplantation 2009; 9: 1859 1867 Wiley Periodicals Inc. C 2009 The Authors Journal compilation C 2009 The American Society of Transplantation and the American Society of Transplant
More informationAntibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients
Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients Lorriana Leard, MD UCSF Transplant Pulmonologist Associate Professor of Clinical Medicine Vice Chief of Clinical Activities Pulmonary, Critical
More informationMicrocirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies
American Journal of Transplantation 2013; 13: 485 492 Wiley Periodicals Inc. Brief Communication C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationHistological picture of antibody-mediated rejection without donor-specific anti-hla
DR ALEKSANDAR SENEV (Orcid ID : 0000-0002-6196-4669) MR. MAARTEN COEMANS (Orcid ID : 0000-0001-8442-3673) Article type : Original Article Histological picture of antibody-mediated rejection without donor-specific
More informationNo evidence of C4d association with AMR However, C3d and AMR correlated well
C4d positivity Poor prognostic factor Reversal to C4d negativity did not change prognosis, with current therapy Prognostic factor for CAV Variable time line for CAV/death No correlation with cellular rejection
More informationDr Ian Roberts Oxford. Oxford Pathology Course 2010 for FRCPath Illustration-Cellular Pathology. Oxford Radcliffe NHS Trust
Dr Ian Roberts Oxford Oxford Pathology Course 2010 for FRCPath Plan of attack: Diagnostic approach to the renal biopsy Differential diagnosis of the clinical syndromes of renal disease Microscopy Step
More informationPosttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
More informationPrimer: histopathology of calcineurin-inhibitor toxicity in renal allografts
Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Peter Liptak and Bela Ivanyi* SUMMARY Calcineurin inhibitors (ciclosporin and tacrolimus) can cause acute and chronic nephrotoxicity.
More informationProgressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes
http://www.kidney-international.org & 2011 International Society of Nephrology see commentary on page 1254 Progressive histological damage in renal allografts is associated with expression of innate and
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationAntibody Mediated Rejection (AMR) in Heart Transplantation Session
Page 1 Antibody Mediated Rejection (AMR) in Heart Transplantation Session Dear Colleagues: The Heart session at Banff this year will be solely focused on AMR and besides the fact that many of us attending
More informationRelationships among injury, fibrosis, and time in human kidney transplants
Relationships among injury, fibrosis, and time in human kidney transplants Jeffery M. Venner,, Jessica Chang, Philip F. Halloran JCI Insight. 2016;1(1):e85323. https://doi.org/10.1172/jci.insight.85323.
More informationThe Force is in the cfdna. Roy D. Bloom MD University of Pennsylvania
The Force is in the cfdna Roy D. Bloom MD University of Pennsylvania Disclosures Advisor: Veloxis, CSL Behring Royalties: UpToDate Research support: CareDx, Veloxis, Shire Nephrocentric presentation Road
More informationAcute renal failure (ARF) in the transplanted kidney represents a
Acute Renal Failure in the Transplanted Kidney Kim Solez Lorraine C. Racusen Acute renal failure (ARF) in the transplanted kidney represents a high-stakes area of nephrology and of transplantation practice.
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationDeján Dobi, MD. PhD Thesis
Clinicopathologic Relevance of Vascular Changes Associated with Transplant Glomerulopathy Secondary to Chronic Antibody-mediated Rejection in the Renal Allograft Deján Dobi, MD PhD Thesis Szeged, 2018
More informationThe diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss
http://www.kidney-international.org 2015 International Society of Nephrology see commentary on page 218 The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk
More informationBanff 2003 Meeting Report: New Diagnostic Insights and Standards
American Journal of Transplantation 2004; 4: 1562 1566 Blackwell Munksgaard Meeting Report Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00585.x Banff 2003 Meeting Report: New Diagnostic
More informationA clear path forward COMING SOON THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
COMING SOON A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test which assesses organ
More informationImpact of Subclinical Rejection on Transplantation
Trends in Transplantation 2007;1:56-60 Impact of Subclinical Rejection on Transplantation David N. Rush for the Winnipeg Transplant Group Transplant Manitoba Adult Kidney Program, University of Manitoba,
More informationThe FDA and Unmet Needs:
The FDA and Unmet Needs: The Path to New Therapy for Transplant Recipients Mark D. Stegall, MD James C. Masson Professor of Surgery Research Departments of Surgery and Immunology Disclosures Ad Board Novartis,
More informationAntibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305
Antibody-Mediated Rejection in the Lung Allograft Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Gerald J Berry, MD Professor of Pathology Stanford University, Stanford, CA
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding
More informationTHE TRANSCRIPTOME OF ENDOTHELIAL PATHOLOGY: RELEVANCE TO ANTIBODY-MEDIATED MICROCIRCULATION INJURY
THE TRANSCRIPTOME OF ENDOTHELIAL PATHOLOGY: RELEVANCE TO ANTIBODY-MEDIATED MICROCIRCULATION INJURY Introduction Banu Sis, MD, FRCPC University of Alberta, Edmonton, AB, Canada In solid organ transplantation,
More informationJoint Banff/CST Program Committee Co-chairs: Dr. Alexandre Loupy and Dr. Prosanto Chaudhury. Joint Banff/CST Finance Committee
2015 Banff/CST Meeting Organizing Corporation ( 2015 MOC ) Co-Directors: Dr. John Gill, Dr. Michael Mengel Members: Anthony Jevnikar, David Rush, Denis Glotz, Kim Solez, Marcelo Cantarovich, Mark Haas,
More informationManagement of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Disclosures Grant support: Bristol-Myers and Squibb Pharmaceuticals,
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationA clear path forward AVAILABLE NOW THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS
AVAILABLE NOW A clear path forward THE LATEST INNOVATION IN KIDNEY TRANSPLANT SURVEILLANCE CAN DRIVE BETTER OUTCOMES FOR YOUR PATIENTS AlloSure is the first and only non-invasive test that assesses organ
More informationThe causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i- IFTA lesion
Received: 31 May 2017 Revised: 25 October 2017 Accepted: 28 October 2017 DOI: 10.1111/ajt.14609 ORIGINAL ARTICLE The causes, significance and consequences of inflammatory fibrosis in kidney transplantation:
More informationPeritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance
ORIGINAL ARTICLE Port J Nephrol Hypert 2008; 22(1): 37-42 Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance Helena
More informationMATERIALS AND METHODS
ORIGINAL ARTICLE Cell Therapy & Organ Transplantation https://doi.org/1.3346/jkms.217.32.6.98 J Korean Med Sci 217; 32: 98-918 Increased Circulating T Lymphocytes Expressing HLA-DR in Kidney Transplant
More informationPharmaceutical pathology
Pharmaceutical pathology Livia Vida 2018 1. Necrosis, types, examples. Apoptosis. 2. Adaptations I. Degeneration, atrophy. 3. Adaptations II. Hypertrophy, hyperplasia. 4. Pigments. Calcification. 5. Inflammation
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationPulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
More informationWhy Do We Need New Immunosuppressive Agents
Why Do We Need New Immunosuppressive Agents 1 Reducing acute rejection rates has not transplanted into better long-term graft survival Incidence of early acute rejection episodes by era Relative risk for
More informationTransplant biopsy beyond light microscopy
Adam and Mengel BMC Nephrology (2015) 16:132 DOI 10.1186/s12882-015-0136-z REVIEW Open Access Transplant biopsy beyond light microscopy Benjamin Adam and Michael Mengel * Abstract Despite its long-standing
More informationBanff Vascularized Composite Allotransplantation
Banff Vascularized Composite Allotransplantation Linda C. Cendales, M.D. Associate Professor of Surgery Duke Health Scholar Director, Vascularized Composite Allotransplantation Duke University Medical
More informationDix ans de transplantation rénale Fonds Boussard
Dix ans de transplantation rénale Fonds Boussard Groupe Spiesser A.T.N. Christophe Legendre, Hôpital Necker & Université Paris Descartes, Paris Fondation Day-Solvay Actualités Néphrologiques Jean Hamburger
More informationKidney Allograft Fibrosis and Atrophy Early After Living Donor Transplantation
American Journal of Transplantation 2005; 5: 1130 1136 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2005 doi: 10.1111/j.1600-6143.2005.00811.x Kidney Allograft Fibrosis and Atrophy Early After
More informationAcute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management
Curr Transpl Rep (2014) 1:78 85 DOI 10.1007/s40472-014-0012-y KIDNEY TRANSPLANTATION (ML HENRY, SECTION EDITOR) Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management Carrie
More informationMonoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH
Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH
More informationThe Natural History of Chronic Allograft Nephropathy
The new england journal of medicine original article The Natural History of Chronic Allograft Nephropathy Brian J. Nankivell, M.D., Ph.D., Richard J. Borrows, M.B., B.Chir., Caroline L.-S. Fung, M.B.,
More informationHLA Antibody Complement Based Assays. Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA
HLA Antibody Complement Based Assays Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA Disclosure Neither presenter has any financial relationships related
More informationDE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
More informationPathology of the late post-transplant kidney and the role of non-t cells
Pathology of the late post-transplant kidney and the role of non-t cells Lynn D. Cornell, M.D. Mayo Clinic, Rochester, Minnesota Banff Conference on Allograft Pathology March 28, 2017 Outline Causes of
More information